Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma

NCT00431561 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

141

Enrollment

INDUSTRY

Sponsor class

Conditions

Glioblastoma
Anaplastic Astrocytoma

Interventions

DRUG: AP 12009 10 µM
DRUG: AP 12009 80 µM
DRUG: temozolomide or PCV
DEVICE: Drug delivery system for administration of AP 12009
PROCEDURE: Placement of Drug Delivery System

Sponsor

Isarna Therapeutics GmbH